Clinical trials: Risperidone
- Drug or intervention Risperidone
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Schizophrenia
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events.
- Trial name
- SHINE (NCT03893825)
- Testing
- TV-46000
- Where
- 90 sites in United States, Bulgaria and 3 more
- Volunteers
- 336 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia, Psychotic Disorders
CAFE Comparison of Atypicals in First Episode of Psychosis
The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day)…
- Conditions
- Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
- Trial name
- NCT00034892
- Testing
- Olanzapine, risperidone
- Where
- 26 sites in United States, Canada
- Sponsor
- AstraZeneca
DCild Development Disorders, Pervasive, Autistic Disorder
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)
The purpose of the study is to evaluate the effectiveness of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral symptoms in children with Pervasive Developmental Disorders…
- Conditions
- DCild Development Disorders, Pervasive, Autistic Disorder, Developmental Disabilities, Asperger Syndrome
- Trial name
- NCT00261508
- Testing
- risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Ortho Inc., Canada
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Disruptive Behavior Disorder
A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
The primary purpose of this study is to document the long-term safety of an oral formulation of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders.
- Trial name
- NCT00236470
- Testing
- risperidone
- Volunteers
- 232 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conduct Disorder, Oppositional Defiant Disorder
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild…
- Conditions
- Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior Disorder
- Trial name
- NCT00250354
- Testing
- Risperidone oral solution
- Volunteers
- 110 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Learning Disorders, Child Behavior Disorders
A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children
The purpose of this study is to assess whether risperidone (an antipsychotic medication) is safe and effective in treating behaviour disorder in learning disabled children, which does not improve with psychological therapy.
- Trial name
- NCT00254930
- Testing
- risperidone
- Volunteers
- 19 people
- Sponsor
- Janssen-Cilag Ltd.
Autistic Disorder in Children and Adolescents
A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder
The purpose of this study is to evaluate the efficacy of risperidone compared with placebo in children and adolescents with irritability associated with autistic disorder.
- Trial name
- NCT01624675
- Testing
- Risperidone
- Where
- 17 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia, Schizoaffective Disorder
Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone
The purpose of the study is to evaluate the characteristics, clinical responses, and safety issues of patients receiving long-term treatment of Risperidone long-acting injectable.
- Trial name
- NCT00644852
- Testing
- Retrospective chart review study
- Volunteers
- 342 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Bipolar Disorder
An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
This study is designed to describe asenapine prescribing patterns in the United Kingdom (UK) during the post-approval period under conditions of usual practice.
- Trial name
- NCT01498770
- Testing
- Asenapine, Aripiprazole, Quetiapine
- Volunteers
- 42 people
- Sponsor
- Organon and Co
Bipolar Disorder
Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents
A clinical study to determine the safety and effectiveness of risperidone compared with placebo in the treatment of bipolar disorder (manic or mixed type) in children and adolescents aged 10 to 17 years.
- Trial name
- NCT00076115
- Testing
- Risperidone
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
The purpose of the study is to assess the safety and effectiveness of risperidone (an antipsychotic medication) in adolescents with schizophrenia over 6 months of treatment.
- Trial name
- NCT00246285
- Testing
- risperidone
- Volunteers
- 381 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit and Disruptive Behavior Disorders
A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
The purpose of this study is to assess the efficacy and safety of risperidone as maintenance therapy to prevent symptoms of relapse in children and adolescents with conduct and other disruptive behavior disorders, who initially…
- Trial name
- NCT00236444
- Testing
- risperidone
- Volunteers
- 375 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conduct Disorder, Disruptive Behavior Disorder
A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the effectiveness and safety of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of conduct disorder in children with mild, moderate, or…
- Conditions
- Conduct Disorder, Disruptive Behavior Disorder, Oppositional Defiant Disorder
- Trial name
- NCT00266552
- Testing
- risperidone
- Volunteers
- 118 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Autistic Disorder, Autism
A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
The purpose of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) and safety and tolerability of the administration of 2 different fixed dose levels of risperidone (an atypical…
- Trial name
- NCT00576732
- Testing
- Risperidone high dose, Risperidone low dose
- Where
- 20 sites in United States
- Volunteers
- 96 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
A clinical study to compare the safety and effectiveness of two different dose ranges of risperidone solution in the treatment of adolescents with a diagnosis of schizophrenia.
- Trial name
- NCT00034749
- Testing
- Risperidone
- Volunteers
- 279 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
The purpose of this study is to evaluate the outcome of medication discontinuation, the safety and effectiveness of re-initiating risperidone long acting injection (RLAI) in case of relapse (the return of a medical problem) of…
- Trial name
- NCT00378092
- Testing
- Oral risperidone, Risperidone Long-Acting Injection (RLAI)
- Where
- South Africa
- Volunteers
- 33 people
- Sponsor
- Janssen Cilag N.V./S.A.
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.